JAZZ

Jazz Pharmaceuticals plc NASDAQ

Healthcare ·Biotechnology ·IE · jazzpharma.com

$208.06

Pre-mkt $209.00 +0.45%

Mkt Cap $13.1B

52w Low $97.50 99.7% of range 52w High $208.40

50d MA $189.97 200d MA $156.39

P/E (TTM) -34.7x

EV/EBITDA 132.8x

P/B 2.9x

Debt/Equity 1.3x

ROE -8.2%

P/FCF 8.0x

RSI (14) —

ATR (14) —

Beta 0.23

50d MA $189.97

200d MA $156.39

Avg Volume 956.2K

About

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 24, 2026	AMC	6.52	6.64	+1.8%	173.83	+3.5%	+13.2%	+8.7%	+9.3%	+9.6%	+7.4%	+8.8%	—
Nov 5, 2025	AMC	5.95	8.13	+36.6%	137.22	+3.7%	-2.3%	-4.4%	-2.9%	-0.1%	-0.4%	+23.7%	—
Aug 5, 2025	AMC	-6.12	-8.25	-34.8%	113.20	-5.0%	-6.4%	-1.0%	-1.7%	-2.2%	+0.1%	+13.1%	—
May 6, 2025	AMC	4.51	1.68	-62.7%	111.17	-5.1%	-8.8%	-11.5%	-12.0%	-6.8%	-7.4%	-2.1%	—
Feb 25, 2025	AMC	5.83	6.60	+13.2%	139.67	+0.6%	+3.2%	+2.6%	+2.8%	+0.4%	-0.5%	-9.5%	—
Nov 6, 2024	AMC	5.47	6.61	+20.8%	111.55	+4.8%	+6.8%	+10.8%	+14.0%	+14.5%	+14.4%	+9.9%	—
Jul 31, 2024	AMC	4.68	5.30	+13.2%	110.25	+2.6%	+3.7%	+2.7%	+1.2%	+1.0%	+1.8%	+5.2%	—
May 1, 2024	AMC	4.14	2.68	-35.3%	110.31	-4.7%	-0.9%	-0.3%	-0.4%	+0.8%	+0.4%	-4.6%	—
Feb 28, 2024	AMC	5.26	5.02	-4.6%	129.70	-3.2%	-8.3%	-8.4%	-9.4%	-8.7%	-9.6%	-8.3%	—
Nov 8, 2023	AMC	4.90	4.84	-1.2%	128.24	+0.2%	-9.1%	-6.3%	-4.9%	-2.7%	-2.2%	-6.1%	—
Aug 9, 2023	AMC	4.46	4.51	+1.1%	133.00	+4.3%	+1.6%	+4.8%	+5.3%	+5.3%	+3.8%	+2.6%	—
May 10, 2023	AMC	4.26	3.95	-7.3%	136.53	+0.3%	+0.4%	-0.6%	-1.4%	-4.0%	-3.2%	-6.9%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 22	Leerink Partners	Maintains	Outperform → Outperform	—	$199.03	$200.74	+0.9%	+1.7%	+0.5%	-1.3%	+1.1%	+2.5%
Apr 20	Barclays	Maintains	Overweight → Overweight	—	$203.42	$206.34	+1.4%	-0.4%	-2.2%	-0.5%	-1.7%	-3.4%
Mar 19	Piper Sandler	Maintains	Overweight → Overweight	—	$180.45	$180.72	+0.1%	+0.7%	+0.1%	+1.0%	+2.5%	+4.8%
Feb 25	Morgan Stanley	Maintains	Overweight → Overweight	—	$173.83	$180.00	+3.5%	+13.2%	+8.7%	+9.3%	+9.6%	+7.4%
Feb 25	RBC Capital	Maintains	Outperform → Outperform	—	$173.83	$180.00	+3.5%	+13.2%	+8.7%	+9.3%	+9.6%	+7.4%
Feb 25	Wells Fargo	Maintains	Overweight → Overweight	—	$173.83	$180.00	+3.5%	+13.2%	+8.7%	+9.3%	+9.6%	+7.4%
Feb 25	BofA Securities	Maintains	Buy → Buy	—	$173.83	$180.00	+3.5%	+13.2%	+8.7%	+9.3%	+9.6%	+7.4%
Jan 12	Truist	Maintains	Buy → Buy	—	$161.13	$162.63	+0.9%	+1.6%	+0.8%	+6.0%	+6.2%	+5.1%
Jan 12	Needham	Maintains	Buy → Buy	—	$161.13	$162.63	+0.9%	+1.6%	+0.8%	+6.0%	+6.2%	+5.1%
Dec 10	Piper Sandler	Maintains	Overweight → Overweight	—	$162.26	$165.35	+1.9%	+1.7%	+1.6%	+3.2%	+4.5%	+4.6%
Nov 24	UBS	Downgrade	Buy → Neutral	—	$176.93	$174.89	-1.2%	+2.2%	+1.8%	-0.0%	-0.2%	-2.7%
Nov 18	BofA Securities	Maintains	Buy → Buy	—	$170.09	$170.09	+0.0%	+6.1%	+3.5%	+3.3%	+4.0%	+6.4%
Nov 18	Baird	Maintains	Outperform → Outperform	—	$170.09	$170.09	+0.0%	+6.1%	+3.5%	+3.3%	+4.0%	+6.4%
Nov 18	Wells Fargo	Maintains	Overweight → Overweight	—	$170.09	$170.09	+0.0%	+6.1%	+3.5%	+3.3%	+4.0%	+6.4%
Nov 17	RBC Capital	Maintains	Outperform → Outperform	—	$141.07	$168.00	+19.1%	+20.6%	+28.0%	+24.8%	+24.6%	+25.4%
Nov 17	Morgan Stanley	Maintains	Overweight → Overweight	—	$141.07	$168.00	+19.1%	+20.6%	+28.0%	+24.8%	+24.6%	+25.4%
Nov 6	RBC Capital	Maintains	Outperform → Outperform	—	$137.22	$142.24	+3.7%	-2.3%	-4.4%	-2.9%	-0.1%	-0.4%
Oct 27	JP Morgan	Maintains	Overweight → Overweight	—	$138.53	$140.00	+1.1%	+0.6%	-0.3%	-2.0%	-1.6%	-0.6%
Oct 20	Morgan Stanley	Maintains	Overweight → Overweight	—	$136.06	$137.18	+0.8%	-0.9%	+1.1%	+1.8%	+1.6%	+1.8%
Sep 24	Morgan Stanley	Maintains	Overweight → Overweight	—	$129.40	$129.80	+0.3%	+0.1%	-1.2%	-1.9%	-0.3%	+1.9%
Aug 29	Goldman Sachs	Maintains	Buy → Buy	—	$126.13	$126.06	-0.1%	+1.3%	+2.8%	+4.4%	+1.5%	+2.7%
Aug 28	Truist	Maintains	Buy → Buy	—	$124.43	$124.43	+0.0%	+1.4%	+2.7%	+4.2%	+5.9%	+2.9%
Aug 28	Morgan Stanley	Maintains	Overweight → Overweight	—	$124.43	$124.43	+0.0%	+1.4%	+2.7%	+4.2%	+5.9%	+2.9%
Aug 28	Needham	Maintains	Buy → Buy	—	$124.43	$124.43	+0.0%	+1.4%	+2.7%	+4.2%	+5.9%	+2.9%
Aug 28	RBC Capital	Maintains	Outperform → Outperform	—	$124.43	$124.43	+0.0%	+1.4%	+2.7%	+4.2%	+5.9%	+2.9%
Aug 20	Needham	Maintains	Buy → Buy	—	$119.20	$119.73	+0.4%	-0.1%	+1.1%	+3.3%	+4.5%	+4.9%
Aug 6	Morgan Stanley	Maintains	Overweight → Overweight	—	$113.20	$107.55	-5.0%	-6.4%	-1.0%	-1.7%	-2.2%	+0.1%
Jul 22	Morgan Stanley	Maintains	Overweight → Overweight	—	$112.65	$112.17	-0.4%	+3.3%	+4.2%	+4.8%	+5.0%	+4.2%
Jun 11	Needham	Maintains	Buy → Buy	—	$113.00	$113.18	+0.2%	-2.2%	-2.4%	-4.0%	-3.0%	-5.3%
Jun 3	Needham	Maintains	Buy → Buy	—	$108.29	$108.81	+0.5%	+1.9%	+1.1%	+0.5%	+2.6%	+3.3%
May 7	Needham	Maintains	Buy → Buy	—	$111.17	$105.51	-5.1%	-8.8%	-11.5%	-12.0%	-6.8%	-7.4%
May 7	Morgan Stanley	Maintains	Overweight → Overweight	—	$111.17	$105.51	-5.1%	-8.8%	-11.5%	-12.0%	-6.8%	-7.4%
May 7	Piper Sandler	Maintains	Overweight → Overweight	—	$111.17	$105.51	-5.1%	-8.8%	-11.5%	-12.0%	-6.8%	-7.4%
May 7	RBC Capital	Maintains	Outperform → Outperform	—	$111.17	$105.51	-5.1%	-8.8%	-11.5%	-12.0%	-6.8%	-7.4%
May 7	Baird	Maintains	Outperform → Outperform	—	$111.17	$105.51	-5.1%	-8.8%	-11.5%	-12.0%	-6.8%	-7.4%
Apr 10	Needham	Maintains	Buy → Buy	—	$110.12	$108.04	-1.9%	-7.3%	-8.7%	-7.6%	-6.5%	-7.8%
Mar 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$138.81	$138.19	-0.4%	-1.0%	-1.4%	-3.3%	-2.0%	-0.6%
Mar 7	UBS	Upgrade	Neutral → Buy	—	$136.45	$139.18	+2.0%	+1.7%	+0.7%	+0.3%	-1.7%	-0.3%
Mar 6	Truist	Maintains	Buy → Buy	—	$140.23	$138.27	-1.4%	-2.7%	-1.0%	-2.0%	-2.4%	-4.3%
Mar 5	Needham	Maintains	Buy → Buy	—	$138.95	$139.28	+0.2%	+0.9%	-1.8%	-0.1%	-1.1%	-1.5%
Feb 27	Barclays	Maintains	Overweight → Overweight	—	$144.17	$142.51	-1.2%	-0.6%	-0.4%	-2.7%	-3.6%	-2.7%
Feb 26	Piper Sandler	Maintains	Overweight → Overweight	—	$139.67	$140.50	+0.6%	+3.2%	+2.6%	+2.8%	+0.4%	-0.5%
Feb 26	JP Morgan	Maintains	Overweight → Overweight	—	$139.67	$140.50	+0.6%	+3.2%	+2.6%	+2.8%	+0.4%	-0.5%
Feb 26	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$139.67	$140.50	+0.6%	+3.2%	+2.6%	+2.8%	+0.4%	-0.5%
Feb 26	RBC Capital	Maintains	Outperform → Outperform	—	$139.67	$140.50	+0.6%	+3.2%	+2.6%	+2.8%	+0.4%	-0.5%
Feb 26	Needham	Maintains	Buy → Buy	—	$139.67	$140.50	+0.6%	+3.2%	+2.6%	+2.8%	+0.4%	-0.5%
Feb 13	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$135.44	$137.65	+1.6%	+1.0%	-1.1%	-0.0%	-0.4%	+0.9%
Dec 12	RBC Capital	Maintains	Outperform → Outperform	—	$120.72	$123.83	+2.6%	+2.4%	+1.9%	+3.7%	+1.5%	+0.8%
Dec 12	Needham	Maintains	Buy → Buy	—	$120.72	$123.83	+2.6%	+2.4%	+1.9%	+3.7%	+1.5%	+0.8%
Dec 12	Piper Sandler	Maintains	Overweight → Overweight	—	$120.72	$123.83	+2.6%	+2.4%	+1.9%	+3.7%	+1.5%	+0.8%

Recent Filings

8-K

Jazz Pharmaceuticals, Inc. -- 8-K Filing

Jazz Pharmaceuticals achieved record $1.2 billion Q4 revenue with 10% YoY growth, positioning the company favorably for 2026 with planned zanidatamab launch and sustained momentum across key products.

Feb 24

Data updated apr 25, 2026 4:40pm · Source: massive.com